Erythropoietin Market Outlook 2022, the market of Europe was valued at US$ 1.4 Billion in 2015
Launch of biosimilars in the erythropoietin market has increased its affordability. European region is the largest market for erythropoietin biosimilar, which makes it a major market for over all erythropoietin drugs as well.
This report provides a detailed analysis of the current and future market scenario of the European erythropoietin market. The report highlights biosimilar erythropoietin at various stages of clinical development. In addition, the report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth.
Based on segment, the report sub-divides the market into biologics and biosimilar. Currently, biologics hold major share in the European market. However, biosimilar market is poised to witness the highest growth due to their cost effectiveness. Based on country, the report segments the market into Germany, France, UK, Italy, and Spain.
Furthermore, the report covers the prevalence and incidences of CKD and cancer for each country under application segmentation. Additionally, the report also provides the patent analysis and pipeline analysis of erythropoietin market.
The last section of the report discusses about the prominent players in European erythropoietin market. A brief business overview and financial information about each of these players has been provided along with their product portfolios.
Key Topics Covered:
1. Analyst View
2. Research Methodology
3. European Protein Therapeutics Market
3.1 Protein Therapeutics Market Vs Pharmaceutical Market
3.2 Current and Future Market Analysis for 2022
3.3 Market Segmentation
4. Erythropoietin Market - Introduction
5. European Erythropoietin Market Outlook by Segment 2022
6. European Erythropoietin Market by Country Outlook 2022
7. Patents and R&D Pipeline Analysis
8. Market Dynamics
8.1.1 Rising Focus on Developing Biosimilars in the Region
8.1.2 Use of Innovative Technologies for EPO Development
8.1.3 Rising Number of Elderly People
8.1.4 Growth in Chronic Diseases Incidences
8.1.5 Growing Pressure to Reduce Healthcare Expenditure in the Region
8.2.1 Expensive Biologics
8.2.2 Side-Effects of EPO
8.2.3 Threat of Substitute for CKD Anemia
9. Key Players Analysis
9.1 Amgen Inc.
9.2 Johnson & Johnson
9.3 Roche Group
9.4 Pfizer Inc.
9.6 Teva Pharmaceuticals Ltd.
9.7 Stada Arzneimittel AG
9.9 3SBio Inc.
9.10 Dr. Reddy's Laboratories
For more information about this report visit http://www.researchandmarkets.com/research/ngsppb/european